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Protein quality control and metabolic homeostasis are integral to maintaining cardiac function during stress; 
however, little is known about if or how these systems interact. Here we demonstrate that C terminus of 
HSC70-interacting protein (CHIP), a regulator of protein quality control, influences the metabolic response 
to pressure overload by direct regulation of the catalytic α subunit of AMPK. Induction of cardiac pressure 
overload in Chip–/– mice resulted in robust hypertrophy and decreased cardiac function and energy generation 
stemming from a failure to activate AMPK. Mechanistically, CHIP promoted LKB1-mediated phosphoryla-
tion of AMPK, increased the specific activity of AMPK, and was necessary and sufficient for stress-dependent 
activation of AMPK. CHIP-dependent effects on AMPK activity were accompanied by conformational changes 
specific to the α subunit, both in vitro and in vivo, identifying AMPK as the first physiological substrate for 
CHIP chaperone activity and establishing a link between cardiac proteolytic and metabolic pathways.
Introduction
Pathological cardiac hypertrophy (subsequently referred to as car-
diac hypertrophy) is an adaptive response to increased afterload 
brought about by hypertension, decreased arterial compliance, 
and other cardiac stressors (1). During the development of cardiac 
hypertrophy, numerous cellular processes come into play, includ-
ing protein synthesis and proteolysis to account for the structural 
changes that accompany hypertrophy, as well as changes in car-
diac metabolism to cope with increased energy demands. Despite 
the well-known fact that protein turnover and metabolic changes 
accompany cardiac hypertrophy, surprisingly little is known about 
how stress-dependent protein quality control mechanisms and 
metabolic regulation are coordinated, if at all, in the heart.
C terminus of HSC70-interacting protein (CHIP, also known as 
STUB1) is a 35-kDa cytosolic protein initially identified in a screen 
for proteins that interact with the mammalian chaperones HSC70, 
HSP70 (2), and HSP90 (3). CHIP is ubiquitously expressed in mam-
malian tissues but is expressed at highest levels in the adult heart 
(2). CHIP plays an important dual role as both a cochaperone and 
a ubiquitin ligase (2–5). More recently, however, an additional role 
for CHIP in protein quality control has been suggested. Evidence 
that CHIP can act as an autonomous chaperone, independent of 
its association with HSPs, has been reported (6). However, these 
observations were made with a nonphysiological substrate (luci-
ferase), and, to date, verification of CHIP’s chaperone activity and 
identification of a physiological substrate have not been made.
Changes in cardiac metabolism, such as oxidative substrate 
preference, mitochondrial function, and biogenesis, play a key 
role in the adaptive response to cardiac stress (7). As cardiomyo-
cyte hypertrophy progresses, energy demand increases and cellu-
lar ATP levels fall. One of the cellular responses to decreased ATP 
levels is the activation of AMP-activated kinase (AMPK) (8–10). 
AMPK is an integral global coordinator of the metabolic stress 
response through its ability to function as a metabolic sensor. The 
AMPK holoenzyme consists of 3 subunits, the catalytic α subunit 
(α1 or α2, the latter being the dominant subunit in the heart; 
ref. 11) and the β and γ regulatory subunits. AMPK is regulated by 
AMPK kinase phosphorylation of the α subunit (for example, by 
the kinase LKB1) and allosterically through the AMP/ATP binding 
domain found in the γ subunit (11). The α2 subunit in particular 
plays a cardioprotective role during pressure overload-induced 
hypertrophy (10) and has recently garnered attention as a thera-
peutic target for cardiac pathologies (12).
Given recent observations linking defective protein quality 
control and cardiac dysfunction (13, 14), we used Chip–/– mice to 
measure the response to acute pressure overload-induced cardiac 
hypertrophy in order to explore the relationship between protein 
quality control mechanisms and cardiac function. Surprisingly, we 
discovered that the cardiac dysfunction associated with pressure 
overload in Chip–/– mice is likely due to the fact that CHIP medi-
ates metabolic adaptation to increased stress by directly regulating 
AMPK activity. This observation not only identifies AMPK as the 
first in vivo chaperone substrate of CHIP but also demonstrates 
that the processes of stress-dependent protein quality control and 
regulation of energy metabolism are not only coordinated but are 
essential for withstanding the increased cardiac demands brought 
about by hemodynamic stress.
Results
Cardiac pressure overload causes pathological hypertrophy and decreased 
cardiac function in Chip–/– mice. CHIP is expressed in both myocytes 
and nonmyocyte cells throughout the heart (Supplemental Figure 
1, A–D; supplemental material available online with this article; 
doi:10.1172/JCI69080DS1). Within myocytes, CHIP expression 
is localized to the sarcomere as well as nuclear and perinuclear 
regions (Figure 1A and Supplemental Figure 1, B–D). To examine 
the consequences of cardiac CHIP deletion during the adaptive 
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response to pressure overload-induced hypertrophy, we subjected 
wild-type and Chip–/– mice to either a sham surgical procedure 
or trans-aortic banding (TAB). During the first 2 to 4 weeks of 
pressure overload, hearts are in a compensatory growth stage, in 
which the increase in resistance caused by the banding is met by an 
increase in ventricular mass to normalize wall stress and maintain 
cardiac output. Surprisingly, 1 week following TAB, Chip–/– mice 
exhibited 35% mortality (compared with no mortality in wild-type 
mice; Figure 1B), markedly enhanced ventricular hypertrophy (Fig-
ure 1C), and a doubling in heart weight across sexes (65% ± 7% 
versus 30% ± 7%, respectively; Figure 1D). Despite these adaptive 
changes, conscious echocardiography revealed that Chip–/– mice 
had a 26.7% ± 7.6% decrease in fractional shortening relative to 
that of wild-type mice that maintained normal cardiac function 
(Figure 1E and Supplemental Table 1). Compared with those 
from wild-type hearts, histological sections from Chip–/– banded 
hearts exhibited the hallmark features of a more acute pathologi-
cal hypertrophic response, including increased myocyte hypertro-
phy and interstitial fibrosis (Figure 1F and Supplemental Figure 
1, E–G). In addition, sections taken from banded Chip–/– hearts also 
contained extensive lipid accumulation (Figure 1F, right). Given 
that cardiac lipid accumulation is seen in pressure-overloaded 
human hearts of individuals with metabolic syndrome (15), and 
is accompanied by decreases in mitochondrial function and bio-
genesis (16), we hypothesized that the discordant increase in car-
diac mass with a decreased cardiac function seen in Chip–/– mice 
after only 1 week of banding could be due to the fact that CHIP is 
required for modifying stress-dependent metabolic responses and/
or mitochondrial function in the heart.
Chip–/– mice have decreased mitochondrial content compared with 
wild-type mice following TAB. To determine whether the decrease 
in cardiac function in banded Chip–/– mice is related to a decrease 
in energy production due to abnormal mitochondrial form or 
function, we used electron microscopy to examine mitochon-
drial structure and volume density after pressure overload in 
both wild-type and Chip–/– hearts. Tissue sections from banded 
Figure 1
Pressure overload-induced cardiac hypertrophy in Chip–/– mice. (A) Indirect immunofluorescence images of CHIP expression (magenta) 
and nuclei (green) in mouse heart. The arrow indicates sarcomere localization; dashed areas indicate nuclear localization (white). Scale bar: 
50 μm. (B) Survival curves after TAB surgery in wild-type or Chip–/– mice (n = 12 and 20, respectively). (C) Hematoxylin and eosin–stained whole 
heart sections from the indicated conditions. Scale bar: 1 mm. (D) Heart weight normalized to tibia length (mg/mm; n = 3 and 6 male and female 
wild-type sham mice, respectively; n = 5 and 8 male and female wild-type TAB mice, respectively; n = 3 and 5 male and female Chip–/– sham 
mice, respectively; n = 8 male and female Chip–/– TAB mice, respectively; P < 0.01 across all sexes and genotypes, sham vs. TAB; ††P < 0.01 
sex-matched wild-type vs. Chip–/– mice). (E) Fractional shortening (%) after sham or TAB surgery (n = 6 and 7 for sham and 8 and 6 for TAB in 
wild-type and Chip–/– mice, respectively; †††P < 0.001 vs. all other groups). (F) Representative histological staining of whole heart sections from 
wild-type and Chip–/– mice. Lectin images represent 25 areas from 4 mice per condition. In Masson trichrome images, numbers represent per-
centage interstitial fibrosis (n = 13). ###P < 0.001 TAB vs. sham; †††P < 0.001 wild-type vs. Chip–/–. Arrows indicate intercellular and intracellular 
regions void of tissue. Scale bar: 100 μm.
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Chip–/– hearts exhibited a 44% and 29% decrease in mitochondrial 
density compared with Chip–/– sham surgery hearts and banded 
wild-type hearts, respectively, with no observable changes in over-
all morphology (such as disputed cristae) that have been observed 
in models of contractile dysfunction (ref. 17, Figure 2A, and Sup-
plemental Figure 2A). In addition, qPCR analysis of the relative 
abundance of mitochondrial DNA normalized to a nuclear DNA 
target revealed that the genomic levels of mitochondrial genes 
were decreased in Chip–/– (but not wild-type) hearts after band-
ing (56% decrease; Figure 2B), confirming the phenotype seen in 
the electron micrographs and suggesting that CHIP is critical for 
maintaining mitochondrial content during cardiac stress.
Pressure overload in Chip–/– hearts causes decreased expression of gene 
clusters related to energy metabolism. Given the numerous pathways 
involved in maintaining mitochon-
drial function, biogenesis, and 
energy metabolic homeostasis, we 
used microarray analysis to analyze 
global changes in gene expression 
in wild-type and Chip–/– mice fol-
lowing TAB (expanded reporting of 
the results obtained from this anal-
ysis is included in the Supplemental 
Methods, Supplemental Table 2, and 
Supplemental Figure 2, B–D). Not 
surprisingly, microarray analysis 
revealed differential expression of 
numerous genes involved in myo-
cyte function (Supplemental Figure 
2C, right), including multiple met-
abolic gene sets, such as oxidative 
phosphorylation (OxPhos), muscle 
contraction, and mitochondrion, 
all of which were downregulated in 
banded Chip–/– mice (Supplemental 
Figure 2C, middle). The OxPhos cat-
egory was the most highly enriched 
functional group between banded 
Chip–/– and wild-type hearts, compris-
ing 9 differentially expressed genes 
encoding for subunits of multiple 
OxPhos complexes (confirmed via 
qPCR; Supplemental Figure 2, E–G, 
and Supplemental Tables 3 and 4). 
One of these differentially expressed 
genes was the transcription factor 
PGC1-α (also known as Ppargc1a), 
which was the fourth most down-
regulated gene comparing banded 
Chip–/– and wild-type hearts (Sup-
plemental Table 2; 2.0-fold change, 
P = 0.00018, confirmed via qPCR; 
Figure 2C). PGC1-α is a primary 
regulator of the OxPhos subunit 
gene transcription as well as a direct 
regulator of mitochondrial biogene-
sis. As such, the decrease in cardiac 
PGC1-α expression in banded Chip–/– 
mice was consistent with a decrease 
in cardiac energy-generating capac-
ity in these mice. To rule out other possible causes for the failure 
of banded Chip–/– mice to generate cardiac energy, we examined 
the expression of Ppara, the gene encoding the nuclear receptor 
PPARα, which is primarily responsible for mediating the switch 
between energy substrates that commonly occurs during cardiac 
stress (18, 19). However, the expression pattern of Ppara and its 
canonical target gene Acox1 did not differ between banded wild-
type or Chip–/– hearts (Figure 2C), suggesting a more global defect 
in energy generation, rather than a defect in the ability to switch 
from one energy substrate to another, is the primary metabolic 
defect in banded Chip–/– hearts. Taken together, the stress-depen-
dent decrease in PGC1-α expression in the banded Chip–/– hearts, 
along with the decreased mitochondrial content (Figure 2, A 
and B) and transcription of nuclear-encoded components of the 
Figure 2
Pressure overload-induced changes in mitochondrial biogenesis and cardiac gene expression in Chip–/– 
mice. (A) Electron micrographs and mitochondrial volume density (represented by the mean ± SEM, 
n > 5 mice represented per condition) in heart sections. Scale bar: 2 μm. (B) Log2 of mean-centered 
DNA levels measured via qPCR of nuclear (H19) or mitochondrial (Nd1, Cytb, Co1, and the mito-
chondrial mean) DNA (represented by the mean ± SEM from 6 biological replicates per condition). 
The surgery-dependent percentage change (Δ) in mean mitochondrial biogenesis (TAB vs. sham) in 
wild-type vs. Chip–/– mice is significant at P = 0.004. (C) Log2 of mean-centered mRNA levels in mouse 
hearts measured via qPCR (represented by the mean ± SEM from 4 biological replicates); changes 
in Ppara and Acox1 are significant at the level of surgery (P < 0.0001), with no significant difference 
between wild-type and Chip–/– mice at either sham or TAB conditions. (D) Total ATP levels and ADP/
ATP ratios in mouse hearts measured via HPLC (represented by the mean ± SEM from 4 biological 
replicates per condition). **P < 0.01 surgery-genotype interaction via 2-way ANOVA; post-hoc test, 
#P < 0.05, ##P < 0.01, and ###P < 0.001 sham vs. TAB surgery; †P < 0.05, ††P < 0.01, and †††P < 0.001 
Chip–/– vs. wild-type genotypes.
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OxPhos pathways (Supplemental Figure 2G), suggest a pivotal role 
for CHIP in regulating cardiac ATP generation and the metabolic 
stress response at a global level.
To test the theory that CHIP is involved in ATP generation, 
adenine nucleotide levels (ATP and ADP) were compared in hearts 
isolated from Chip–/– and wild-type mice after 1 week of either 
sham or TAB surgery. This early time point following banding 
was chosen due to the quick decline in the survival of Chip–/– mice 
following the induction of pressure overload (Figure 1B). Follow-
ing 1 week of banding, total ATP levels in extracts isolated from 
wild-type mice increased 1.8 fold (Figure 2D and Supplemental 
Table 5), consistent with recent metabolic studies demonstrating 
energetic adaptation to maintain cardiac power during the initial 
compensation to pressure overload (20, 21). In contrast, total ATP 
levels failed to increase in extracts isolated from Chip–/– banded 
hearts, supporting the theory that CHIP may be involved in ATP 
generation during cardiac pressure overload. Despite the lack of 
increase in ATP levels, banded Chip–/– hearts did contain elevated 
ratios of total ADP/ATP, a phenotype consistent with either accel-
erated ATP consumption or disruption of ATP synthesis (22). In 
metabolically healthy systems, a rise in the ADP/ATP ratio (ampli-
fied further by the AMP/ATP ratio through the myokinase reac-
tion) is a physiological cue to restore ATP homeostasis through 
the activation of the energy-sensing kinase AMPK (22). The activa-
tion and increased activity of AMPK promotes multiple ATP-gen-
erating pathways, including PGC1-α–dependent mitochondrial 
biogenesis pathways, while at the same time inhibiting energy-con-
suming processes, such as protein synthesis. Given the elevated 
ratios of ADP/ATP in banded Chip–/– hearts, without a concomi-
tant increase in ATP levels, we hypothesized that a failure of activa-
tion of AMPK may be responsible for the inability of Chip–/– hearts 
to maintain energy homeostasis in response to pressure overload.
Deficient AMPK activation, signaling, and activity during pressure over-
load in Chip–/– hearts. As a first step in determining whether there is 
a defect in the AMPK signaling pathway in banded Chip–/– hearts, 
the activation and activity of the catalytic subunits of AMPK were 
measured after 1 week following sham or TAB surgery in wild-
type and Chip–/– hearts (Figure 3A). The primary readout of AMPK 
activation, phosphorylation of AMPKα-T172, was substantially 
decreased in banded Chip–/– hearts, as was phosphorylated ACC (a 
well-characterized in vivo AMPK substrate), indicating an inhibi-
tion of AMPK activity. To confirm that AMPK activity was indeed 
inhibited in Chip–/– hearts, we measured the rate of phosphory-
lation of a synthetic AMPK substrate (SAMS peptide) in immu-
noisolated AMPKα1 and AMPKα2 complexes. Consistent with 
the decrease in ACC phosphorylation (Figure 3A), SAMS phos-
phorylation was also decreased in Chip–/– banded hearts (Figure 
3B), confirming an inhibition of AMPK activity. Taken together, 
these data demonstrate that, in Chip–/– banded hearts, AMPK acti-
vation (illustrated by phosphorylated AMPKα-T172) and activity 
(illustrated by phosphorylated ACC and SAMS) are significantly 
inhibited, offering a plausible explanation for why Chip–/– hearts 
fail to compensate and maintain energy homeostasis in response 
to pressure overload.
LKB1 is the primary kinase involved in the energy status–depen-
dent phosphorylation of AMPKα-T172 in the heart (23). To deter-
mine whether decreases in LKB1 activity or expression contribute 
to the lack of AMPK activation and activity in banded Chip–/– 
hearts, we measured the rate of phosphorylation of a synthetic 
LKB1 substrate as well as steady-state LKB1 protein expression 
levels. Surprisingly, both LKB1 activity (Figure 3B) and expression 
(Figure 3C) were increased 2.0 and 2.8 fold, respectively, in Chip–/– 
banded hearts, suggesting that the deficit in AMPK activation in 
these hearts is not due to decreased LKB1 activity or expression.
Collectively, these phenotypes in the Chip–/– banded hearts are 
consistent with a loss in AMPK function in response to a need for 
increased cardiac power and ATP (Figure 3, A–C). A recent genetic 
model determined a critical role for AMPKα2 (the predominant 
AMPK catalytic subunit in the heart) in response to pressure over-
load in which levels of pAKT-S273 and p4EBP1-T70, key regula-
tors of protein translation usually inhibited by AMPK signaling, 
were increased in response to banding in AMPKα2–/– hearts (24). 
AKT and 4EBP1 are not substrates of AMPK but instead regulate 
global protein translation and are responsive to the activity levels 
of AMPK (10, 24, 25). Consistent with our hypothesis of reduced 
AMPK function in banded Chip–/– hearts, we observed a nearly 
identical increase in the activation of these pathways (Figure 3D) 
to those found in the banded AMPKα2–/– hearts. Notably, CHIP 
expression itself was increased approximately 30% in wild-type 
mouse hearts after 1 week of TAB (Figure 3D), a trend that contin-
ued through longer periods of pressure overload (Supplemental 
Figure 3A) and correlated with increased AMPK activation and 
activity (Supplemental Figure 3, A and B). An additional known 
target of AMPK, estrogen-related receptor α (ERRα) expression 
(26), was also decreased in banded Chip–/– hearts (Supplemental 
Figure 3C). ERRα regulates mitochondrial biogenesis indepen-
dently of PGC1-α (26, 27), and our observation of decreased ERRα 
and PGC1-α expression is consistent with reduced AMPK function 
and decreased mitochondrial biogenesis in banded Chip–/– hearts. 
These results indicate that, despite allosteric cues (increased ADP/
ATP ratio) and increased expression of LKB1, AMPK activation 
and activity are significantly diminished in banded Chip–/– hearts, 
suggesting that either proteins regulated by CHIP or CHIP itself 
plays a key role in AMPKα activation and activity toward down-
stream targets during cardiac pressure overload.
CHIP is required for AMPK activation in response to stress. Our pre-
vious data suggest that, whereas CHIP is not required for AMPK 
activation under basal conditions, CHIP is essential for optimal 
activation of AMPK in response to pressure overload. However, it 
is not known whether the reliance on CHIP expression is specific 
to stress caused by pressure overload or whether it occurs also in 
other metabolic stress models involving AMPK. To test this, we 
cultured mouse embryonic fibroblasts (MEFs) isolated from either 
wild-type or Chip–/– mice, induced acute oxidative stress and ATP 
depletion via H2O2 exposure, and measured the AMPK response. 
As previously shown (28), AMPK activation and activity increased 
substantially in wild-type MEFs in response to H2O2 exposure, as 
measured by phosphorylation of AMPKα-T172 and SAMS phos-
phorylation (Figure 3E and Supplemental Figure 3D). In contrast, 
AMPK activation and activity were markedly attenuated in Chip–/– 
MEFs; however, this attenuation in both AMPK activation and 
activity could be reversed by the reintroduction of CHIP (Figure 
3E and Supplemental Figure 3D), confirming that CHIP is essen-
tial for proper stress-dependent activation of AMPK. Interestingly, 
AMPK activation was also rescued by treatment of Chip–/– MEFs 
with the mutant construct CHIP-K30A (Figure 3E) that is unable 
to bind with HSP70/90 (29), indicating that the ability of CHIP 
to activate AMPK is not reliant on CHIP’s direct interaction with 
HSPs and is therefore unlikely to be due to the cochaperone func-
tion of CHIP. The ability of CHIP to activate AMPK was also tested 
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in mice using the AMPK agonist AICAR (which is metabolized to 
ZMP, an AMP mimetic). In these experiments, as in the cell culture 
experiments, AICAR activation of AMPK was found to be depen-
dent on the presence of CHIP (Supplemental Figure 3E). These 
data demonstrate that CHIP is required for AMPK activation in 
response to a variety of stressors. However, whether or not CHIP 
interacts directly with AMPK, or through mediation via another 
protein, remains unknown.
Figure 3
AMPK pathway and activity during pressure overload. (A) Representative immunoblots and densitometry analysis of AMPKα, pAMPKα-T172, 
pACC-S79, and ACC after sham or TAB surgery in wild-type or Chip–/– (KO) mouse hearts. (B) AMPKα1, AMPKα2, total AMPK, and LKB1 activity 
determined by phosphorylation of SAMS (pSAMS) or LKB1 (pLKBtide) peptides in immunoprecipitates from heart lysates (represented by the 
mean ± SEM from 3–6 biological replicates per condition). (C and D) Representative immunoblots and densitometry analysis of (C) LKB1 and (D) 
pAKT-S473, AKT, p4EBP1-T70, 4EBP1, and CHIP protein after sham or TAB surgery. Relative cardiac protein levels from A, C, and D normalized 
to GAPDH are expressed as mean ± SEM from 3 to 6 biological replicates per condition. *P < 0.05, **P < 0.01, ***P < 0.001 surgery-genotype 
interaction via 2-way ANOVA; post-hoc test, #P < 0.05, ##P < 0.01, and ###P < 0.001 sham vs. TAB surgery; †P < 0.05, ††P < 0.01, and †††P < 0.001 
Chip–/– vs. wild-type genotypes. (E) Representative immunoblots and densitometry analysis of protein extracts from wild-type or Chip–/– MEFs 
treated with adenoviruses as labeled followed by exposure to H2O2. Relative protein levels of phosphorylated AMPKα-T172 normalized to β-actin 
are expressed as mean ± SEM from 3 independent experiments. **P < 0.01, ***P < 0.001 via Dunnett’s comparison to wild-type GFP control 
condition and control-treated cells for each genotype/adenovirus pairing. The dashed line indicates the amount of phosphorylation in wild-type 
cells in response to H2O2.
research article
 The Journal of Clinical Investigation   http://www.jci.org   Volume 123   Number 8   August 2013 3593
CHIP forms a complex with AMPK in vivo and directly interacts with 
AMPK in vitro. To determine whether CHIP interacts with AMPK, 
we performed coimmunoprecipitation assays on purified heart 
extracts from wild-type mice. Both α1 and α2 AMPK catalytic sub-
units (including the active, phosphorylated form, AMPKα-T172) as 
well as the β1, β2, and γ2 regulatory subunits coeluted with CHIP 
immunoprecipitation (Figure 4A and Supplemental Figure 4, A 
and B), confirming that CHIP forms a complex with AMPK holoen-
zymes in the heart. Quantitative analysis of the cardiac proteome 
demonstrated that CHIP protein exists in over a 3:1 molar ratio to 
AMPKα2 (30), demonstrating that abundance of CHIP and AMPK 
protein in the heart are sufficient for CHIP to make substantial 
Figure 4
Analysis of the CHIP-AMPK interaction. (A) Immunoblot analysis from CHIP or control (IgG) immunoprecipitations in wild-type and Chip–/– heart 
lysates. (B) Immunoprecipitations of reactions containing recombinant CHIP, AMPKα1β1γ1, AMPKα2β1γ1, or combined proteins, subsequently 
immunoblotted with the indicated antibodies. (C) Densitometry of AMPKα-T172 phosphorylation (pT172) and AMPK activity measured by SAMS 
phosphorylation (pSAMS) in reactions containing combinations of proteins as indicated. Relative pT172 was normalized to total AMPKα. Data 
are represented by the mean ± SEM from 3 independent experiments (2-way ANOVA, †P < 0.05, ††P < 0.01,comparing time; ‡P < 0.05, ‡‡P < 0.01, 
and ‡‡‡P < 0.0001, comparing the presence of CHIP; t test, *P < 0.05 and **P < 0.01, comparing the presence of CHIP per time point). (D) 
Activated pAMPKα1β1γ1 (pα1, green) and pAMPKα2β1γ1 (pα2, blue) activity in the absence or presence of CHIP (+C) measured by SAMS 
phosphorylation (represented by mean ± SEM from 3 independent experiments) (ANOVA post-hoc test, ***P < 0.001 comparing all pairs of 
conditions). Values were normalized to control conditions (0.5 hours in the absence of CHIP); “#” indicates activity measurements not signifi-
cantly above background. The samples were also immunoblotted for total AMPKα1 or AMPKα2 from the indicated conditions. (E) AMPK activity 
measured by pSAMS (represented by mean ± SEM from 3 biological replicates) using reactions containing either activated pAMPKα1β1γ1 
(green) or pAMPKα2β1γ1 (blue) mixed with increasing amounts of recombinant CHIP. Dashed green and blue lines represent baseline activ-
ities of pα1β1γ1 and pα2β1γ1, respectively.
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contributions to AMPK function (Supplemental Table 6). The evi-
dence of a CHIP-AMPK complex suggested that CHIP functions 
directly with AMPK to increase both its activation and activity. The 
two known molecular functions of CHIP are as a ubiquitin ligase, 
to mediate either the polyubiquitination of chaperone-bound pro-
teins for eventual degradation by the proteasome, or as a cochap-
erone, to assist heat shock chaperones in the refolding of damaged 
or unfolded proteins. Given the positive effect of CHIP on AMPK 
function, as well as the ability of the K30A mutant to rescue the 
Chip–/– phenotype in response to stress, CHIP did not appear to be 
functioning in either of these capacities with respect to regulating 
AMPK activity or activation. A newly proposed function of CHIP 
is as an autonomous chaperone, acting independently of other 
molecular chaperones to recognize and bind misfolded proteins. 
However, to date, this role for CHIP has only been demonstrated 
on luciferase, a nonphysiological substrate ligand (6). Therefore, 
to test whether CHIP acts as an autonomous chaperone to AMPK, 
we established an in vitro system whereby the interaction between 
CHIP and AMPK could be studied without the influence of extra-
neous molecules and in the absence of the HSP cochaperone and 
ubiquitin ligase functions of CHIP. Evidence of direct interaction 
between recombinant CHIP and AMPK in solution was demon-
strated through coimmunoprecipitation of a CHIP-AMPK com-
plex with antibodies that recognize either AMPK or CHIP (Figure 
4B). The CHIP-AMPK complex formed independent of other cel-
lular cofactors and consisted of the trimeric AMPK holoenzyme 
(irrespective of α-T172 phosphorylation status) and a CHIP dimer, 
the well-defined in vivo functional oligomeric state of CHIP (ref. 6 
and Supplemental Figure 4, C–F).
CHIP directly increases AMPK activation and functions as an AMPK 
agonist independent of extraneous factors. Chaperones function though 
transient interactions with substrates until a particular conforma-
tion is achieved (31). Activation of AMPK by upstream kinases, 
dephosphorylation by phosphatases, and activity of AMPK are 
regulated allosterically primarily through conformational changes 
throughout the AMPK molecule. Consequently, we next tested 
CHIP’s influence on the multiple mechanisms that can influence 
AMPK phosphorylation and activity using our in vitro model. In 
the reaction without CHIP, LKB1 robustly phosphorylated and 
activated AMPK holoenzymes in vitro. However, when CHIP was 
present, phosphorylation of AMPK holoenzymes occurred more 
rapidly (<5 minutes) prior to saturation (>10 minutes) (Figure 4C). 
Similar CHIP-dependent effects were measured with LKB1-medi-
ated phosphorylation of monomeric AMPKα2 (Supplemental 
Figure 4G). Surprisingly, in the presence of CHIP, AMPK holoen-
zyme-specific activity determined by SAMS phosphorylation was 
increased even when AMPKα-T172 phosphorylation levels were 
identical to those in the treatment conditions in which CHIP was 
absent (Figure 4D), suggesting that CHIP can enhance AMPK 
activity independent of α-T172 phosphorylation.
Next, we tested the ability of CHIP to protect activated AMPK 
from PP2Cα-mediated dephosphorylation at α-T172 in the pres-
ence and absence of AMP binding to the regulatory γ subunit of 
AMPK. The presence of CHIP did not blunt the dephosphoryla-
tion of AMPK holoenzymes or change the AMP-dependent attenu-
ation of dephosphorylation (Supplemental Figure 4H), suggesting 
CHIP does not affect AMPKγ subunit function. In the absence of 
PP2Cα, CHIP once again increased AMPK activity (Supplemental 
Figure 4H, bottom) without any change in the phosphorylation 
levels of α-T172 (Supplemental Figure 4H, top). The CHIP-depen-
dent increase in AMPK activity independent of α-T172 phospho-
rylation is consistent with our similar observation in the LKB1 
phosphorylation assays (Figure 4C), again suggesting CHIP- 
dependent effects on the kinase activity of AMPK consistent with 
our chaperone model.
An additional mechanism of chaperone function is to help main-
tain substrate stability and solubility. Recombinant proteins vary 
in their stability at physiological temperatures. Activated AMPK 
maintains 100% stability for up to 2 hours at 37°C but loses all 
measurable activity after 20 hours at 37°C (Figure 4D). Remark-
ably, coincubation of CHIP with the activated AMPK holoenzyme 
resulted in the complete retention of AMPK activity after 20 hours. 
A similar affect of CHIP on protein stability was also observed with 
monomeric AMPKα2 (Supplemental Figure 4G), demonstrating 
that CHIP can affect AMPK stability in vitro and elicit effects spe-
cifically toward the catalytic (α) subunit of AMPK.
In all of our in vitro experiments measuring AMPK activity (Fig-
ure 4, C and D, and Supplemental Figure 4, H and I), reactions 
containing both activated AMPK and CHIP consistently resulted 
in higher SAMS phosphorylation compared with reactions con-
taining activated AMPK alone, consistent with CHIP functioning 
as an AMPK agonist independent of α-T172 phosphorylation. 
To directly test the agonist function of CHIP, and to rule out any 
nonspecific artifacts in our experiments, we confirmed that CHIP 
exhibited no kinase activity itself toward either AMPKα-T172 
(Figure 4C) or SAMS peptide (data not shown) and that the pres-
ence of CHIP did not result in nonspecific binding of radiolabeled 
phosphate (Supplemental Figure 4I). However, CHIP did directly 
increase activated AMPK kinase activity in a dose-dependent man-
ner that resulted in a 2.5- and 40-fold increase in α1- and α2-con-
taining AMPK complexes, respectively (Figure 4E), including 
significant increases in activity at submicromolar concentrations 
of CHIP (Supplemental Figure 4J). This is the first such report 
of an endogenous AMPK agonist that directly affects the cata-
lytic subunit independent of phosphorylation that, unlike other 
AMPK agonists, does not act as a low-energy AMP mimetic. Taken 
together, these data ascribe a new function to CHIP as being an 
AMPK agonist that directly augments the ability of AMPK to reg-
ulate energy metabolism in the heart during periods of stress, a 
finding that has immense therapeutic value.
CHIP alters AMPK tertiary structure. Given that AMPK activation 
and activity are augmented through conformational changes, such 
as the conformation rearrangement of the autoinhibitory domain 
(AID), the α-hook, and nucleotide binding to the γ subunit, we 
hypothesized that CHIP’s ability to increase AMPK activation and 
activity may involve a change to the tertiary structure of AMPK. To 
determine whether CHIP is able to induce conformational changes 
to AMPK, we used both in vitro and in vivo systems. For the in vitro 
studies, we used limited proteolysis analysis, which is predicated 
on the fact that the accessibility of specific protein residues recog-
nized by proteases is dependent on the native 3-dimensional form 
of the protein. Therefore, incubating intact folded proteins with 
low amounts of proteases and examining the resultant fragments 
can detect structural changes through changes in the protease site 
susceptibility. Using recombinant proteins in conditions identical 
to those used to measure functional CHIP-dependent functional 
changes in AMPK (Figure 4, C and D) and limited proteolysis anal-
ysis (32), we determined that the proteolytic fingerprint (trypsin) 
of the α subunit of the activated AMPK holoenzyme (pAMPK-
α2β1γ1) was markedly changed in the presence of CHIP (Figure 
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Figure 5
CHIP-dependent effects on AMPK tertiary structure. (A) Limited proteolysis analysis of pAMPKα2β1γ1 in the presence of either luciferase (Luc) 
or CHIP. (B) Specific activity of AMPK in the presence of luciferase or CHIP prior to protease treatment (represented by mean ± SEM; Student’s 
t test, **P < 0.01; n = 3). (C) Nondigested pAMPKα2β1γ1 (A) or fragments of limited proteolysis reactions containing pAMPKα2β1γ1 in the 
presence of either luciferase (L) or CHIP (C) visualized with SYPRO-Ruby gel stain. (A and C) The white arrows indicate intact AMPKα2; the 
green arrows indicate intact γ1 subunit; and the red arrow indicates a fragment of AMPKα2 determined via protein sequencing that was detected 
only reactions containing CHIP. (D) Sequence of human AMPKα2 protein. The outlined area indicates the kinase domain, with the sequences 
identified by mass spectroscopy (red). (E) Representative live cell micrographs from before and after photobleaching conditions for both YFP and 
CFP channels and the resulting image ratio (CFPpost/pre) for cells cotransfected with a control vector (top) or CHIP expression vector (bottom). 
(F) Quantification of the apparent FRET efficiencies of AMPKα2 protein (cyan) or the positive control FRET protein (gray) coexpressed with the 
indicated vectors on the x axis (n = 45 cells from 3 independent transfections; ***P < 0.001 compared with pcDNA3 conditions; †P < 0.05 and 
‡‡P < 0.01 compared with CHIP and CHIP(K30A), respectively, via ANOVA).
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5A, right) compared with that in the presence of luciferase (Figure 
5A). CHIP’s effect appeared to be localized to the catalytic sub-
unit (consistent with the potent effect of CHIP on increasing the 
specific activity of AMPK; Figure 5B), given that there was no dif-
ference in the γ subunit fingerprint, which was completely intact 
when the pAMPKα2 holoenzyme was incubated with either CHIP 
or luciferase (Figure 5A, bottom). We confirmed CHIP-dependent 
conformational changes in the proteolytic fingerprints using pro-
teinase K in place of trypsin (Supplemental Figure 5A). In an effort 
to better localize the specific regions within the α subunit subject 
to CHIP-induced conformational changes, we resolved the prote-
olytic fragments in identical conditions via SDS-PAGE and visual-
ized them with a protein stain to identify intact portions of AMPK 
that were present only in reactions containing CHIP. As expected, 
in reactions containing a molar excess of either luciferase or CHIP 
relative to AMPK, the predominant proteolytic fragments iden-
tified via sequencing were luciferase or CHIP (Figure 5C, lanes 2 
and 3). However, we also identified a unique fragment in the reac-
tions containing CHIP (Figure 5C, red arrow, and Supplemental 
Table 7) that corresponded to the intact protein kinase domain 
of AMPKα2 (NCBI GenInfo Identifier: 110590560), with peptide 
coverage that spans residues 13–256 (Figure 5D, red). Identical to 
the immunoblot data for the γ subunit, we identified the intact 
full-length γ1 band in the same reactions via mass spectroscopy 
sequencing (Figure 5C, green arrow, and Supplemental Table 7). 
Given the size and content of the intact α subunit fragment 
(approximately 42 kDa) it is likely that CHIP affects C-terminal 
regions of AMPKα, which include the α-hook regulatory domain 
or components of the β subunit interaction domain. Taken 
together, these data are consistent with CHIP altering the tertiary 
structure of the AMPK holoenzyme.
To determine whether CHIP also influences AMPKα folding 
or structure in vivo, we created a tricistronic YFP-AMPKα2-CFP 
vector (33, 34) to use with acceptor pho-
tobleaching, a form of fluorescent reso-
nance energy transfer (FRET) that detects 
changes in 3-dimensional space between 
2 fluorophores. We initially confirmed that 
the tricistronic vector incorporated into 
intact holoenzyme molecules, responded 
to agonist, and was functionally active 
(Supplemental Figure 5, B–E). Measur-
able FRET efficiency (E) of YFP-AMPKα2- 
CFP was only detected with coexpres-
sion of CHIP, both wild-type CHIP 
(E = 9.3%, range 2.0%–17.3%) and mutants 
that abolish either the HSP-interacting 
motif or ubiquitin ligase domain of CHIP 
(E = 9.7% and 5.6%, respectively), demon-
strating that CHIP expression results in 
conformational changes to AMPKα that 
force the distance between the 2 fluoro-
phores to a distance less than 10 nm (the 
Förster radius) or reorientation of their 
relative diploes (35). The effect of CHIP on 
FRET was specific to the AMPKα2 insert, 
as CHIP had no effect on a positive FRET 
control YFP-CFP vector. This in vitro and 
in vivo data demonstrating CHIP-depen-
dent conformational changes to AMPKα 
offers a plausible mechanism by which CHIP is able to directly 
influence AMPK activation. The sum total of the data presented 
here supports a direct role for CHIP in regulating cardiac metabo-
lism and function via specific chaperoning activity on AMPK.
Discussion
Along with CHIP’s well-documented role as a both a ubiquitin 
ligase and cochaperone (29), an additional role for CHIP in pro-
tein quality control has been suggested due to the autonomous 
chaperone activity of CHIP that is independent of its associations 
with HSPs (6). However, before now, no known physiological 
substrate for CHIP’s chaperone activity has been identified. The 
data presented here demonstrate that CHIP acts as a molecular 
chaperone to AMPK, inducing conformational changes to the 
α catalytic subunit both in vitro and in vivo (Figure 5, A, C, E, 
and F, and Supplemental Figure 5A), thereby regulating not only 
AMPK stability (Figure 5D) and activation (Figure 3, A, E, and C; 
Supplemental Figure 3E; and Supplemental Figure 4G), but also 
directly increasing the rate of activated AMPK’s ability to phos-
phorylate its substrate (Figure 4E and Supplemental Figure 4J). 
The influence of CHIP expression in mediating AMPK activation 
and activity appears to be essential for maintaining cardiac func-
tion in the acute response to pressure overload, thereby suggesting 
a direct link between cardiac protein quality control mechanisms 
and regulators of cardiac energy metabolism. Uniquely, these 
molecular actions are independent of CHIP’s interactions with the 
HSP family of chaperones (Figure 3E and Supplemental Figure 
3C). In addition, the steady-state expression level of a well-char-
acterized CHIP ubiquitin ligase substrate, serum- and glucocorti-
coid-regulated kinase SGK (36), was not increased in Chip–/– mice 
during pressure overload (Supplemental Figure 3C). Although this 
does not preclude other CHIP ubiquitin ligase substrates from 
contributing to the pressure overload phenotype, this observa-
Figure 6
Proposed physiological model for the CHIP-dependent effects on the regulation of AMPK func-
tion. In unstressed conditions, CHIP forms a complex that contains the AMPK holoenzyme; 
however, the consequence of this interaction is not understood, as CHIP does not appear to 
directly affect either baseline AMPK activation status, depicted by phosphorylation at α-T172 
(P), or baseline AMPK activity (indicated by the star). In cell stress conditions, such as oxidative 
stress and cardiac pressure overload, or in the presence of AMPK agonists, CHIP is necessary 
for LKB1-mediated activation of AMPK, as observed by increased phosphorylation of the α 
(catalytic) subunit, which leads to an increase in AMPK activity. In addition to increasing LKB1-
mediated phosphorylation of AMPK, in cell-free systems, CHIP robustly increases AMPK activity 
independent of phosphorylation, acting as a chaperone of AMPK, amplifying the positive effect of 
CHIP on AMPK activity. CHIP may also play a key role in the recovery phase in returning the cell 
to metabolic homeostasis. CHIP mediates polyubiquitination of LKB1, leading to degradation of 
LKB1 via a proteasome-dependent mechanism that may contribute to restoring AMPK activation 
status to baseline levels.
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stretch of residues that comprise an AID that is sufficient for a con-
formational-dependent inhibition of kinase activity (39, 40) as well 
as the α-hook domain that propagates conformational changes 
across the AMPK subunits (41). Given the regulatory role of both 
the AID and α-hook on allosteric regulation of AMPK function, 
and conversely the ability of CHIP to directly mediate increases in 
AMPK substrate turnover (Figure 4E), CHIP chaperone activity 
potentially alters either of these domains, as demonstrated by our 
limited proteolysis analysis (Figure 5, A, C, and D, and Supplemen-
tal Figure 5A). The chaperone activity of CHIP appears to directly 
affect the catalytic α subunit compared with other well-character-
ized AMPK agonists that are either indirect effectors or low-energy 
mimetics (such as ZMP) that target the regulatory γ subunit; there-
fore, the AMPK agonist function of CHIP described here is unique 
to any known biological or synthetic effector molecule of AMPK.
Further characterization of our CHIP chaperone model will be 
needed to elucidate the exact interaction between AMPK and CHIP 
and the physiological repercussions of AMPK conformational 
changes. Chaperones function through a constant transition of 
substrate-bound and -unbound states until a stable or altered 
conformation of the substrate is reached. This likely explains 
how increasing CHIP concentrations in excess of a 2:1 molar ratio 
can have such a potent effect on AMPK activity by increasing the 
likelihood of interaction (Figure 4E and Supplemental Figure 4J). 
The continued increase in AMPK activity when CHIP is in molar 
excess is distinct from CHIP’s cochaperone activity of augmenting 
HSC70 activity. Interestingly, we found no further increase in the 
ability of CHIP to alter HSC70 activity whether CHIP is used in 
molar excess or molar equivalency (2). The results from our chap-
erone model also predict that changes in local concentrations of 
CHIP in vivo, either through increases in expression or through 
localization, would elicit potent effects on AMPK activation and 
activity. It is interesting to note that AMPKα2-containing com-
plexes preferentially localize to the nucleus under stress conditions 
(42), much like the redistribution of CHIP during stress (43), sug-
gesting that CHIP may also chaperone the rather uncharacterized 
nuclear functions of AMPK (42). Although this study focuses pri-
marily on the role of CHIP during acute periods of stress, CHIP- 
dependent regulation of AMPK may also play a broader role in met-
abolic homeostasis during aging. We previously characterized an 
accelerated aging phenotype in Chip–/– mice (44). In isolated skel-
etal and cardiac muscle, we observed decreased levels of AMPKα- 
T172 phosphorylation in aging Chip–/– mice relative to that in age-
matched controls (our unpublished observations). Recent studies 
highlight the role for AMPK as a key regulator in aging through 
regulation of PGC1-α and mitochondrial biogenesis (45) as well 
as a protective role for AMPKα2 in age-induced defects in heart 
function (17). Taken together, these studies suggest that the role 
of CHIP on aging may extend to AMPK-dependent pathways. Fur-
thermore, our results, taken in context of previous studies, offer 
the possibility that regulating the mechanisms that trigger AMPK 
and CHIP interactions may prove to be an efficacious strategy to 
combat both acute and chronic metabolic diseases.
Methods
Further details are provided in the Supplemental Methods.
Global gene expression microarrays. Complete, MIAME-compliant data sets 
are archived with the Gene Expression Omnibus of the National Center 
for Biotechnology Information and are accessible through the GEO series 
accession no. GSE24209.
tion is consistent with the fact that ubiquitin ligase activity is not 
required for the direct effect of CHIP on AMPK both in vitro and 
in cell-based models (Supplemental Figure 4G and Figure 5F). The 
ability of CHIP to interact with and regulate α1- and α2-contain-
ing holoenzymes, in addition to other CHIP substrates, likely con-
tributes to the more rapid onset and severe cardiac hypertrophy in 
response to pressure overload in Chip–/– mice (Figure 1) compared 
with the inactivation of only the AMPKα2 gene (10). It also bares 
noting that the overall effect of CHIP on the pressure overload 
phenotype reported here may in fact be underestimated, given the 
35% mortality in Chip–/– mice.
Interestingly, Chip–/– mice at baseline (or under sham surgery con-
ditions) are essentially healthy in regards to cardiac function, sug-
gesting that CHIP is dispensable for baseline regulation of AMPK. 
This also suggests that there are adaptive physiological mechanisms 
capable of compensating for the loss of CHIP expression. This adap-
tation may account for the enhanced cardiac metabolic phenotype 
observed in Chip–/– mice at baseline that includes increased mito-
chondrial content (Figure 2B) and trends toward increased mito-
chondrial volume (Figure 2A), ATP content (Figure 2D), and AMPK 
activity (pACC in Figure 3A and pSAMS in Figure 3B); these changes 
also likely contribute to the enhanced diastolic function measured 
in sham-operated Chip–/– mice (13% increase; Supplemental Table 1). 
As seen in both Chip–/– mice and several AMPK knockout and trans-
genic mouse lines, neither CHIP nor AMPK are essential to cardiac 
development or normal growth and function. However, the impor-
tance of both molecules becomes vastly apparent under stressful 
conditions, with CHIP and AMPK activating protein quality control 
and energy homeostatic pathways, respectively.
The CHIP and AMPK pathways have previously not been 
thought to work in a coordinated manner; however, in cell cul-
ture models, CHIP does promote the polyubiquitination of LKB1, 
resulting in decreased LKB1 protein levels (37). Likewise, transient 
silencing of CHIP expression leads to an increase in LKB1 protein 
expression (37), suggesting another possible intersection between 
the CHIP and AMPK pathways. Following TAB surgery in Chip–/– 
mice, we observed a stress-dependent 4-fold increase in LKB1 pro-
tein levels (Figure 3C) and a 2-fold increase in LKB1 activity (Fig-
ure 3B) following induction of pressure overload, consistent with 
a role for CHIP in regulating LKB1 protein expression. However, 
in these Chip–/– hearts with increased LKB1 expression and activ-
ity, AMPK was still not activated (Figure 3, A and B), supportive 
of CHIP functioning in a dual role in regulating AMPK activity 
under stressful conditions. That is, whereas CHIP may in fact be 
a bona fide E3 ligase for LKB1 under stress conditions, it also 
enhanced LKB1-mediated phosphorylation (Figure 4C) and was 
necessary for stress-induced activation of AMPK (Figure 3E). This 
places CHIP in a unique regulatory role, one in which it is capable 
of fine-tuning the stress-mediated activation of AMPK by promot-
ing its activation, enhancing its activity, and attenuating the signal 
through the degradation of LKB1 (Figure 6). This is similar to the 
role CHIP plays in mediating the heat shock stress response both 
at the level of initiation and also in levels returning to baseline 
(38). Furthermore, the observation of modest increases in CHIP 
expression in both pressure overload (Figure 3D) and AICAR-stim-
ulated mice (Supplemental Figure 3E) may be the result of a feed-
back loop necessary for regulating stress-induced pathways that 
can contribute to the regulation of AMPK activity.
Previous studies of AMPK provide clues to the structure-function 
relationship between CHIP and AMPKα. Both α1 and α2 contain a 
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parison or Bonferroni post-hoc tests where appropriate. Additional statis-
tical tests used are indicated in the figure legends. GraphPad Prism was 
used for all calculations. P < 0.05 was considered statistically significant.
Study approval. All animal procedures were approved by the Institu-
tional Animal Care and Use Committee of The University of North Car-
olina at Chapel Hill.
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AMPK phosphorylation and activity assays. Protein complexes were isolated 
by immunoprecipitation using AMPKα1, AMPKα2, pan-AMPKα, or LKB1 
antibodies. Kinase activity was determined by measuring the amount of 
SAMS or LKB1 peptide phosphorylation as described previously (46). 
AMPK phosphorylation by LKB1/STRADα/MO25α was measured as 
described previously (47) in the presence of recombinant CHIP where indi-
cated. AMPK activity using purified proteins was assayed using the SAMS 
peptide as described previously (46).
Limited proteolysis analysis of AMPK holoenzyme. AMPKα2β1γ1 was incu-
bated alone or in the presence of luciferase or CHIP for 30 minutes and 
then digested with increasing amounts of trypsin or proteinase K for 
1 hour and analyzed by immunoblotting as described previously (48).
Twisted FRET plasmid and assay. The full-length cDNA encoding rat 
AMPKα2 from plasmid 15991 (Addgene; ref. 49) was PCR subcloned into 
pCR 2.1-TOPO. The purified XhoI/EcoRI restriction fragment was ligated 
into EYPF-ECFP (provided by B.K. Berdiev; ref. 33), resulting in the EYFP- 
AMPKα2-ECFP vector. Transient transfection of COS7 cells was used 
with the twisted FRET (double-tagged ECFP-EYFP) method as previously 
described (33, 34) to quantify changes in AMPKα2 protein conformation 
in live cells. Apparent FRET efficiency (E) was calculated using emission 
spectra before and after photobleaching (Dpre and Dpost, respectively) using 
the following equation: E = (Dpost – Dpre)/Dpost corrected for bleaching effi-
ciency as described previously (50).
Statistics. Data are presented as mean ± SEM. Significance was evaluated 
using either 2-way or 1-way ANOVA, with Newman-Keuls multiple com-
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